GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Pre-Tax Income

HLS Therapeutics (TSX:HLS) Pre-Tax Income : C$-37.74 Mil (TTM As of Mar. 2024)


View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. HLS Therapeutics's pretax income for the three months ended in Mar. 2024 was C$-8.30 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was C$-37.74 Mil. HLS Therapeutics's pretax margin was -49.19%.

During the past 13 years, HLS Therapeutics's highest Pretax Margin was 23.00%. The lowest was -46.90%. And the median was -30.39%.


HLS Therapeutics Pre-Tax Income Historical Data

The historical data trend for HLS Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Pre-Tax Income Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.95 -20.88 -15.11 -32.23 -37.30

HLS Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.98 -12.38 -9.91 -7.15 -8.30

Competitive Comparison of HLS Therapeutics's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Pre-Tax Income falls into.



HLS Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

HLS Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-13.884+-12.15+-11.736+0.47+-0.00099999999999767
=-37.30

HLS Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-4.694+-0.242+-3.553+0.185+0
=-8.30

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-37.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics  (TSX:HLS) Pre-Tax Income Explanation

HLS Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-8.304/16.883
=-49.19%

During the past 13 years, HLS Therapeutics's highest Pretax Margin was 23.00%. The lowest was -46.90%. And the median was -30.39%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (TSX:HLS) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.
Executives
Polar Asset Management Partners Inc. 10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines